Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging technologies for HER2 testing.

Marc van de Vijver1

  • 1Department of Pathology, The Netherlands Cancer Institute, NL-1066 CX Amsterdam, The Netherlands. m.vd.vijver@nki.nl

Oncology
|November 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

The Lancet. Digital health·2025
Same author

Obesity-associated changes in molecular biology of primary breast cancer.

Nature communications·2023
Same author

Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial.

International journal of radiation oncology, biology, physics·2020
Same author

A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy.

Cancer research·2019
Same author

Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens.

Virchows Archiv : an international journal of pathology·2018
Same author

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Nature·2017

Accurate HER2 testing is crucial for Herceptin therapy in metastatic breast cancer (MBC). Current methods like immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) have variability, prompting research into new techniques.

Area of Science:

  • Oncology
  • Biomarker Detection
  • Clinical Diagnostics

Background:

  • HER2-positive status is essential for Herceptin therapy in metastatic breast cancer (MBC).
  • Current HER2 testing methods, immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH), are widely used but susceptible to variability.
  • Interlaboratory variability and technical factors can affect the accuracy and reproducibility of IHC and FISH assays.

Purpose of the Study:

  • To review the current landscape of HER2 testing in breast cancer.
  • To discuss emerging technologies for HER2 assessment.
  • To highlight the need for validated and reproducible HER2 testing methods.

Main Methods:

  • Review of current clinical practices for HER2 testing.
  • Discussion of established methods: Immunohistochemistry (IHC) and Fluorescence In-Situ Hybridization (FISH).

Related Experiment Videos

  • Exploration of novel techniques: Polymerase Chain Reaction (PCR), Chromogenic In-Situ Hybridization (CISH), and Enzyme-Linked Immunosorbent Assay (ELISA) for HER2 extracellular domain (ECD).

    • Main Results:

    • IHC and FISH are standard but face challenges with variability and standardization.
    • Emerging methods like PCR, CISH, and ELISA offer potential for improved HER2 assessment.
    • No widespread standard testing algorithm currently exists for HER2 detection.

    Conclusions:

    • Accurate and reproducible HER2 testing is critical for guiding Herceptin therapy in breast cancer patients.
    • New technologies like PCR, CISH, and ELISA show promise but require validation against current standards (IHC/FISH).
    • Standardization and validation are necessary before novel HER2 detection methods can be adopted into routine clinical practice.